A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis

NS-018 is a Janus-activated kinase 2 (JAK2)-selective inhibitor, targeting the JAK–signal transducer and activator of transcription (STAT) pathway that is deregulated in myelofibrosis. In this phase I, dose-escalation portion of a phase I/II study, patients with myelofibrosis received oral NS-018 in...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Leukemia
Main Authors: Verstovsek, S, Talpaz, M, Ritchie, E, Wadleigh, M, Odenike, O, Jamieson, C, Stein, B, Uno, T, Mesa, R A
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2017
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5292677/
https://ncbi.nlm.nih.gov/pubmed/27479177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.215
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker